Stoke Therapeutics (STOK) Stock Forecast & Price Target

Compare

389 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

STOK Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Stoke

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

STOK Stock 12 Month Forecast

Average Price Target

$24.80

▲(116.03%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $24.80 with a high forecast of $35.00 and a low forecast of $18.00. The average price target represents a 116.03% change from the last price of $11.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","36":"$36","12.75":"$12.75","20.5":"$20.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.75,20.5,28.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,13.446153846153846,15.242307692307692,17.03846153846154,18.834615384615386,20.630769230769232,22.426923076923078,24.223076923076924,26.01923076923077,27.815384615384616,29.611538461538466,31.407692307692308,33.20384615384616,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,12.661538461538463,13.673076923076923,14.684615384615384,15.696153846153846,16.70769230769231,17.71923076923077,18.73076923076923,19.74230769230769,20.753846153846155,21.765384615384615,22.776923076923076,23.78846153846154,{"y":24.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,12.138461538461538,12.626923076923077,13.115384615384615,13.603846153846154,14.092307692307692,14.580769230769231,15.069230769230769,15.557692307692308,16.046153846153846,16.534615384615385,17.02307692307692,17.51153846153846,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$24.80

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$12.5

Buy

8.89%

Upside

Upgraded

06/05/25

Stoke Therapeutics earns a strong overall score due to its robust financial performance, highlighted by revenue growth and improved profitability. The technical analysis supports this with positive momentum indicators. Valuation metrics are favorable, underscoring the stock's attractiveness. Corporate events, though not directly weighted, enhance the company's market positioning and growth prospects.

Joseph StringerNeedham

Needham

$22

Buy

91.64%

Upside

Reiterated

07/01/25

Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment

Andrew FeinH.C. Wainwright

H.C. Wainwright

$47→$35

Buy

204.88%

Upside

Reiterated

05/15/25

Stoke Therapeutics' Zorevunersen: A Promising First-in-Class Therapy for Dravet Syndrome with Strong Commercial Potential

Marc GoodmanLeerink Partners

Leerink Partners

$18

Buy

56.79%

Upside

Reiterated

05/14/25

Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/13/25

Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$20

Buy

74.22%

Upside

Reiterated

05/13/25

Stoke Therapeutics: Strategic Positioning and Financial Health Drive Buy Rating Amid Upcoming Phase 3 Trial for Dravet Syndrome Treatment

Thomas ShraderBTIG

BTIG

$29

Buy

152.61%

Upside

Reiterated

05/13/25

Stoke Therapeutics' Promising Outlook: Buy Rating Backed by Zorevenersen's Potential and Strong Financial Position

Rudy LiChardan Capital

Chardan Capital

$24

Buy

109.06%

Upside

Reiterated

03/19/25

Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (NASDAQ: INTS) and Stoke Therapeutics (NASDAQ: STOK)

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

01/08/25

Cantor Fitzgerald reiterates Overweight Rating on Stoke Therapeutics (STOK)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Stoke Therapeutics (NASDAQ: STOK).

Jessica FyeJ.P. Morgan

J.P. Morgan

$15

Hold

30.66%

Upside

Reiterated

11/06/24

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Immatics (NASDAQ: IMTX)

Laura ChicoWedbush

Wedbush

$17

Buy

48.08%

Upside

Reiterated

07/11/24

Stoke Therapeutics (STOK) Receives a Buy from Wedbush

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$12.5

Buy

8.89%

Upside

Upgraded

06/05/25

Joseph StringerNeedham

Needham

$22

Buy

91.64%

Upside

Reiterated

07/01/25

Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment

Andrew FeinH.C. Wainwright

H.C. Wainwright

$47→$35

Buy

204.88%

Upside

Reiterated

05/15/25

Stoke Therapeutics' Zorevunersen: A Promising First-in-Class Therapy for Dravet Syndrome with Strong Commercial Potential

Marc GoodmanLeerink Partners

Leerink Partners

$18

Buy

56.79%

Upside

Reiterated

05/14/25

Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/13/25

Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$20

Buy

74.22%

Upside

Reiterated

05/13/25

Stoke Therapeutics: Strategic Positioning and Financial Health Drive Buy Rating Amid Upcoming Phase 3 Trial for Dravet Syndrome Treatment

Thomas ShraderBTIG

BTIG

$29

Buy

152.61%

Upside

Reiterated

05/13/25

Stoke Therapeutics' Promising Outlook: Buy Rating Backed by Zorevenersen's Potential and Strong Financial Position

Rudy LiChardan Capital

Chardan Capital

$24

Buy

109.06%

Upside

Reiterated

03/19/25

Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (NASDAQ: INTS) and Stoke Therapeutics (NASDAQ: STOK)

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

01/08/25

Cantor Fitzgerald reiterates Overweight Rating on Stoke Therapeutics (STOK)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Stoke Therapeutics (NASDAQ: STOK).

Jessica FyeJ.P. Morgan

J.P. Morgan

$15

Hold

30.66%

Upside

Reiterated

11/06/24

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Immatics (NASDAQ: IMTX)

Laura ChicoWedbush

Wedbush

$17

Buy

48.08%

Upside

Reiterated

07/11/24

Stoke Therapeutics (STOK) Receives a Buy from Wedbush

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stoke Therapeutics

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+1.12%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +1.12% per trade.

3 Months

xxx

Success Rate

16/34 ratings generated profit

Average Return

+4.97%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +4.97% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

10/16 ratings generated profit

Average Return

+42.56%

reiterated a buy rating 2 months ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +42.56% per trade.

2 Years

xxx

Success Rate

10/16 ratings generated profit

Average Return

+31.47%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +31.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

STOK Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, STOK has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. STOK average Analyst price target in the past 3 months is 24.80.

Each month's total comprises the sum of three months' worth of ratings.

STOK Financial Forecast

STOK Earnings Forecast

Next quarter’s earnings estimate for STOK is -$0.49 with a range of -$0.68 to -$0.03. The previous quarter’s EPS was $1.90. STOK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year STOK has Outperformed its overall industry.

STOK Sales Forecast

Next quarter’s sales forecast for STOK is $9.39M with a range of $1.50M to $36.00M. The previous quarter’s sales results were $158.57M. STOK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year STOK has Outperformed its overall industry.

STOK Stock Forecast FAQ

What is STOK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 24.80.

What is STOK’s upside potential, based on the analysts’ average price target?

Stoke Therapeutics Inc has 116.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is STOK a Buy, Sell or Hold?

Stoke Therapeutics Inc has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Stoke Therapeutics Inc’s price target?

The average price target for Stoke Therapeutics Inc is 24.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $18.00. The average price target represents 116.03% Increase from the current price of $11.48.

What do analysts say about Stoke Therapeutics Inc?

Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of STOK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Stoke Therapeutics (STOK) Stock Forecast & Price Target

STOK Analyst Ratings

STOK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stoke Therapeutics

STOK Analyst Recommendation Trends

STOK Financial Forecast

STOK Earnings Forecast

STOK Sales Forecast

STOK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts